
**Supplemental Figure 1:** *Correlation between alemtuzumab levels and CD14/15 chimerism post-HSCT*. Alemtuzumab levels measured at 14 days after transplant were plotted against the CD14/15 chimerism (% donor) measured at 2, 4, 6, 12, and 24 months after transplant for each patient on a scatter plot. Regression lines are included in each panel. There were no statistically significant correlations.



PK vs CD14/15 Chimerism (%)

🛨 Alem-TBI 🔺 Pento-Cy-Alem-TBI